How Many Units Is a Microdose in an Ozempic or Wegovy Pen?

One of the most common questions in microdosing forums is mechanical, not medical: how many clicks, or how many units, is a "microdose" in an Ozempic or Wegovy pen? People reach for this question because a branded pen is expensive and they want to stretch it, or because they want a dose below the lowest step on the official ladder. This page answers the math honestly — but the honest answer comes with a warning that the marketing around microdosing tends to bury: the way these pens are built, click-counting to hit a custom sub-dose is exactly what the manufacturer designed against, and it is an easy way to dose yourself wrong.

So we'll do two things. We'll explain how the pens actually deliver dose — and why "18 clicks ≈ 0.25 mg" is a rough folk-conversion, not a manufacturer instruction. And we'll be clear that if your real goal is a controlled low dose, a compounded vial measured in true units is a more honest tool than improvising on a fixed-dose pen — with its own caveats, which we cover in how to reconstitute and measure a compounded GLP-1 microdose.

First, the honest framing: there is no approved "microdose"

Before any math: no GLP-1 manufacturer makes a microdose, and no trial has tested intentional microdosing. The Wegovy and Ozempic labels define a fixed ladder of approved doses, and the lowest rung — 0.25 mg once weekly for semaglutide — is a starter dose meant to build tolerance on the way up, not a maintenance dose proven to do much on its own ¹. A "microdose" sits below even that starter step, in territory no label and no randomized trial covers ². Everything below is about the mechanics of the device, not an endorsement that a sub-starter dose works.

How the pens actually deliver a dose

This is where Ozempic and Wegovy differ, and the difference matters for anyone counting clicks.

The Ozempic pen is a multi-dose, dial-a-dose device. A single Ozempic pen is designed to deliver several fixed doses from one cartridge — you dial the dose, and the pen meters it out. The pen audibly clicks as it dials, which is the origin of the "count the clicks" folklore. The Ozempic label specifies the discrete doses the pen is built to give (for example 0.25 mg and 0.5 mg from the lower-strength pen) and instructs the user to dial to the marked dose, not to an arbitrary point between marks ³.

The Wegovy single-dose pen is the opposite. Most Wegovy pens are single-use, fixed-dose injectors: one pen, one pre-set dose, no dial. There is nothing to "count" — you press and the full pre-set dose goes in. That design makes Wegovy essentially impossible to microdose without physically defeating the device, which is not a thing the label contemplates or supports ¹.

So the "how many units is a microdose" question is really an Ozempic-pen question, dressed up.

The folk math — and why it's only folk math

Here is the conversion people circulate, stated plainly so we can then knock it down. Ozempic's lower-strength pen holds 2 mg of semaglutide in 1.5 mL and is built to give 0.25 mg or 0.5 mg doses ³. People who count clicks report that a full 0.25 mg dose corresponds to roughly 18–19 clicks on that pen, so they reason that "half a click is half the drug" and dial a fraction to chase a microdose.

The arithmetic is internally consistent, but it rests on assumptions the manufacturer never validated:

• •The pen is not graduated for sub-doses. Its dose window shows the approved doses, not units. Stopping between marks means you are estimating, not measuring ³.
• •Click-to-dose linearity is assumed, not guaranteed. A consistent dose depends on a full, uninterrupted press to the stop; partial actuations can under-deliver unpredictably, and air or priming losses are not evenly distributed across "clicks."
• •It voids the one thing a fixed-dose pen is good at — accuracy. The entire reason a dial-a-dose pen exists is to remove guesswork; counting clicks to a custom number puts the guesswork back.

This is why the clinical literature that addresses microdosing treats pen manipulation as a safety hazard — flagging dosing errors and device misuse rather than offering a clicks-to-milligrams chart ². We are giving you the folk math so you understand what people mean, not because it's a reliable way to dose a potent drug.

Why a compounded vial is the more honest low-dose tool

If your actual goal is a deliberately low, measured dose, the device built for that is a vial and a syringe — not a fixed-dose pen you're fighting against. With a compounded vial of known concentration (say, milligrams per milliliter), you draw a true volume in insulin-syringe units, and the dose is something you can calculate and repeat rather than estimate by ear. That's why most people who microdose in practice use compounded product, not a manipulated brand pen ².

But "more honest tool" is not "safe and proven." Compounded GLP-1s are not FDA-approved finished drugs, and a pharmacovigilance analysis of compounded GLP-1 agonists found markedly elevated reporting odds for preparation errors (reporting odds ratio roughly 48.9), contamination (about 19.0), and compounding problems (about 8.5), alongside more reports of abdominal pain, gallbladder inflammation, and hospitalization ⁴. So the trade is real: a vial lets you measure a low dose accurately, but it shifts you onto a grey-market product with its own documented risks. We dig into that in is compounded / microdosed GLP-1 safe? and walk through legitimate access routes in how to get microdosing tirzepatide.

What even a correctly measured low dose can — and can't — promise

Suppose you nail the measurement. The deeper problem remains: a sub-therapeutic dose is, by definition, below where the benefits were demonstrated. Semaglutide works by mimicking the gut hormone GLP-1 — slowing gastric emptying, suppressing glucagon, and acting on appetite centers in the brain — and those effects depend on enough drug being present to occupy enough receptors ⁵. Dose-finding data show weight loss shrinking steadily as the dose falls: in a phase 2 dose-ranging trial, semaglutide produced about 6% weight loss at 0.05 mg versus roughly 14% at the top dose tested ⁶, and the headline STEP 1 result (about 14.9% mean loss) came from the full 2.4 mg dose ⁷. A microdose sits below even the lowest dose in that trial. Getting the units right doesn't change the dose-response reality, which we cover in GLP-1 dose-response: why lower doses do less.

The bottom line on clicks and units

The clicks-to-milligrams conversion people pass around (roughly 18 clicks per 0.25 mg on the low-strength Ozempic pen) exists, and we've explained it — but it's folklore layered on top of a device that was engineered specifically to prevent improvised dosing. Novo Nordisk discourages click-counting because a fixed-dose pen's whole value is accuracy, and counting clicks to a custom sub-dose throws that away and invites dosing error ²³. Wegovy's single-dose pens can't be microdosed at all without defeating the device. If you genuinely want a controlled low dose, a compounded vial measured in real units is the more honest instrument — but it carries its own compounding and contamination risks ⁴, and no amount of careful measurement makes a sub-therapeutic dose match the benefits proven at the full dose ⁶⁷. Talk to a qualified clinician before improvising with any GLP-1 device.

For the bigger picture, start with our pillar, microdosing GLP-1: what the evidence actually shows, and our deep dive on microdosing semaglutide. For a visual map of where doses sit, see our GLP-1 microdosing dose chart, and to compare providers, our GLP-1 microdose rankings hub.